# Approaches To Therapy Escalation In T2D

> **NCT03813316** · PHASE4 · WITHDRAWN · sponsor: **LMC Diabetes & Endocrinology Ltd.**

## Conditions studied

- Type2 Diabetes

## Interventions

- **DRUG:** DPP-4 inhibitor
- **DRUG:** SGLT2 inhibitor
- **DRUG:** SGLT2 inhibitor and DPP-4 inhibitor

## Key facts

- **NCT ID:** NCT03813316
- **Lead sponsor:** LMC Diabetes & Endocrinology Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-05-01
- **Primary completion:** 2019-09-18
- **Final completion:** 2019-09-18
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of funding availability to complete project
- **Last updated:** 2019-09-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03813316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03813316, "Approaches To Therapy Escalation In T2D". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03813316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*